Safety and Efficacy of Immune Checkpoint Inhibitors in Patients on Dialysis: A Retrospective Case Series

Am J Kidney Dis. 2020 Aug;76(2):299-302. doi: 10.1053/j.ajkd.2020.02.451. Epub 2020 May 15.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenal Gland Diseases / chemically induced
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents, Immunological / therapeutic use*
  • B7-H1 Antigen / antagonists & inhibitors
  • CTLA-4 Antigen / antagonists & inhibitors
  • Carcinoma, Merkel Cell / complications
  • Carcinoma, Merkel Cell / drug therapy
  • Female
  • Head and Neck Neoplasms / complications
  • Head and Neck Neoplasms / drug therapy
  • Humans
  • Hypothyroidism / chemically induced
  • Kidney Failure, Chronic / complications
  • Kidney Failure, Chronic / therapy*
  • Lung Neoplasms / complications
  • Lung Neoplasms / drug therapy
  • Male
  • Melanoma / complications
  • Melanoma / drug therapy
  • Middle Aged
  • Myocarditis / chemically induced
  • Myositis / chemically induced
  • Neoplasms / complications
  • Neoplasms / drug therapy*
  • Pneumonia / chemically induced
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors
  • Renal Dialysis*
  • Retrospective Studies
  • Skin Neoplasms / complications
  • Skin Neoplasms / drug therapy
  • Treatment Outcome
  • Urogenital Neoplasms / complications
  • Urogenital Neoplasms / drug therapy

Substances

  • Antineoplastic Agents, Immunological
  • B7-H1 Antigen
  • CD274 protein, human
  • CTLA-4 Antigen
  • CTLA4 protein, human
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor